Is XLV a good investment?

State Street Health Care Select Sector SPDR ETF (XLV) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores XLV 5.5 out of 10 — highest on Growth (7.9), lowest on Valuation (3.5). It trades at 30.3 times earnings, against its own median of 24.7. Its ten largest holdings are 61% of the fund.

Updated September 11, 2026

How is XLV rated? ETF Copilot scores State Street Health Care Select Sector SPDR ETF (XLV) 5.5 out of 10

As of September 11, 2026, ETF Copilot scores State Street Health Care Select Sector SPDR ETF (XLV) 5.5 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 5.5 / 10
Growth: 7.9 / 10
Valuation: 3.5 / 10
Risk: 7.4 / 10
Quality: 4.7 / 10
Return: 3.6 / 10

What is XLV's expense ratio? 0.08% a year

As of September 11, 2026, XLV charges 0.08% a year, yields 1.80% and holds $43.4B in assets across 59 positions.

State Street Health Care Select Sector SPDR ETF (XLV) — cost, income and size
Measure	XLV
Expense ratio	0.08%
Dividend yield	1.80%
Assets under management	$43.4B
Holdings	59

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in XLV's data

U.S. healthcare sector, weighted by market value.

Trades at a richer price than most health-sector peers — you pay more for each dollar of earnings.

Its trailing EBITDA multiple of 18.7x sits above the category median of 15.9x, among the priciest in the group. P/E multiple of 30.3x tells the same story.

A core healthcare allocation, priced for the stability the sector is known for.

Why did XLV move this week? It fell 4.6% in the week to September 11, 2026 — Eli Lilly and Amgen drove it

XLV fell 4.6% in the week to September 11, 2026. The holdings that moved it most were Eli Lilly (−3.8%), Amgen (−15.0%) and Johnson & Johnson (−4.6%); HCA Healthcare (+4.3%) pushed the other way.

Is XLV expensive right now? It trades at 30.3 times earnings, against its own median of 24.7

As of September 11, 2026, XLV is more expensive than 87% of its own 114 monthly readings since 2017 — 99 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside XLV?

What's inside XLV: Size (Large 95%, Mid 6%, Small 0%); Geography (International 2%, US 98%); AI 0.4%.

What are XLV's top holdings? The ten largest are 61% of the fund

Eli Lilly, Johnson + Johnson, Abbvie, Merck, UnitedHealth, Thermo Fisher Scientific, Amgen, Abbott Laboratories, Gilead Sciences and Pfizer are XLV's largest holdings, in that order.

More concentrated than 79% of Healthcare & Biotech ETFs.

Half of XLV's weight sits in its 7 largest positions, and once those weights are taken into account it behaves like 18 equally weighted holdings.

Cite this

ETF Copilot, “State Street Health Care Select Sector SPDR ETF (XLV) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/xlv